News & Updates

Drug use affects chemotherapy completion in elderly ovarian cancer patients

12 May 2020

In elderly adults with ovarian cancer, potential drug interactions (PDIs) may interfere with chemotherapy completion, while polypharmacy (PP) and potentially inappropriate medications (PIMs) pose mortality risks, a recent study has shown.

Drug use affects chemotherapy completion in elderly ovarian cancer patients

12 May 2020

Trametinib improves PFS in low-grade serous ovarian or peritoneal cancer

12 May 2020 by

Treatment with trametinib, an MEK inhibitor, significantly improves progression-free survival (PFS) in patients with recurrent low-grade serous ovarian or peritoneal carcinoma (LGSOC) compared with standard of care (SOC), according to a study presented at SGO 20/20.

Trametinib improves PFS in low-grade serous ovarian or peritoneal cancer

12 May 2020

Atezolizumab plus enzalutamide does not improve OS or cancer control vs enzalutamide in metastatic CRPC

12 May 2020 by

Atezolizumab, given in combination with enzalutamide, did not show improvement in overall survival (OS) or cancer control compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC), resulting in early termination of the phase III IMbassador250 study.

Atezolizumab plus enzalutamide does not improve OS or cancer control vs enzalutamide in metastatic CRPC

12 May 2020

Pneumonitis history linked to ICI/chemo-related pneumonitis in NSCLC patients

12 May 2020 by

Patients with advanced non-small-cell lung cancer (NSCLC) who have a past medical history of pneumonitis are at increased risk of treatment-related pneumonitis (TAP) from immune checkpoint inhibitor (ICI) regimens or chemotherapy alone, an analysis of clinical trial and real-world data has shown.

Pneumonitis history linked to ICI/chemo-related pneumonitis in NSCLC patients

12 May 2020

Adding trastuzumab to chemo improves survival in HER2+ uterine serous carcinoma

11 May 2020 by

Adding trastuzumab to a chemotherapy backbone of carboplatin and paclitaxel led to sustained survival benefit in patients with recurrent/advanced, HER2-positive uterine serous carcinoma compared with chemotherapy alone, according to an updated survival analysis presented at SGO 2020 Meeting.

Adding trastuzumab to chemo improves survival in HER2+ uterine serous carcinoma

11 May 2020

Biosimilar for metastatic colorectal cancer as effective as bevacizumab

11 May 2020 by

The bevacizumab biosimilar BE1040V for the treatment of metastatic colorectal cancer (mCRC) has met the noninferiority margin in a phase III trial.

Biosimilar for metastatic colorectal cancer as effective as bevacizumab

11 May 2020

Greater chemo use confers small survival benefit in elderly prostate cancer patients

09 May 2020

In the era of combination chemotherapy (CCE), clinical practice for treating elderly patients with metastatic prostate cancer (mPC) appears to be changing despite limited data, a recent study has shown.

Greater chemo use confers small survival benefit in elderly prostate cancer patients

09 May 2020

Extragonadal steroids influence androgen receptor activity, castration resistance in prostate cancer

08 May 2020

Extragonadal steroids have significant contributions to the activation of the androgen receptor axis pathway at castration levels of testosterone in patients with recurrent nonmetastatic prostate cancer, suggests a study. In addition, these steroids promote the development of castration resistance following primary local treatment.

Extragonadal steroids influence androgen receptor activity, castration resistance in prostate cancer

08 May 2020

Veliparib continues to show positive signals in ovarian cancer

08 May 2020 by

Subgroup analyses of the VELIA* trial showed that the concomitant administration of the poly(adenosine diphosphate-ribose) polymerase inhibitor veliparib with an induction chemotherapy (CT) regimen comprising carboplatin and paclitaxel (CP) generated antitumour activity and favourable safety in women with high-grade serous ovarian cancer.

Veliparib continues to show positive signals in ovarian cancer

08 May 2020

Pancreatic ductal adenocarcinoma impairs HRQoL in senior patients

07 May 2020

Elderly patients of pancreatic ductal adenocarcinoma suffer from worse health-related quality of life (HRQoL), particularly in terms of physical health status, a recent study has found.

Pancreatic ductal adenocarcinoma impairs HRQoL in senior patients

07 May 2020

News & Updates

Filter by Specialty:

Specialty:

Drug use affects chemotherapy completion in elderly ovarian cancer patients

Drug use affects chemotherapy completion in elderly ovarian cancer patients

Trametinib improves PFS in low-grade serous ovarian or peritoneal cancer

Trametinib improves PFS in low-grade serous ovarian or peritoneal cancer

Atezolizumab plus enzalutamide does not improve OS or cancer control vs enzalutamide in metastatic CRPC

Atezolizumab plus enzalutamide does not improve OS or cancer control vs enzalutamide in metastatic CRPC

Pneumonitis history linked to ICI/chemo-related pneumonitis in NSCLC patients

Pneumonitis history linked to ICI/chemo-related pneumonitis in NSCLC patients

Adding trastuzumab to chemo improves survival in HER2+ uterine serous carcinoma

Adding trastuzumab to chemo improves survival in HER2+ uterine serous carcinoma

Biosimilar for metastatic colorectal cancer as effective as bevacizumab

Biosimilar for metastatic colorectal cancer as effective as bevacizumab

Greater chemo use confers small survival benefit in elderly prostate cancer patients

Greater chemo use confers small survival benefit in elderly prostate cancer patients

Extragonadal steroids influence androgen receptor activity, castration resistance in prostate cancer

Extragonadal steroids influence androgen receptor activity, castration resistance in prostate cancer

Veliparib continues to show positive signals in ovarian cancer

Veliparib continues to show positive signals in ovarian cancer

Pancreatic ductal adenocarcinoma impairs HRQoL in senior patients

Pancreatic ductal adenocarcinoma impairs HRQoL in senior patients